argenx has stopped its Phase 3 UNITY study testing efgartigimod SC in adults with moderate-to-severe Sjögren's disease after an Independent Data Monitoring Committee recommended halting the trial for futility. The study failed to meet its primary endpoint of improving systemic disease activity. Safety results were consistent with previous findings and no new risks emerged. argenx plans to analyze the data thoroughly to gain insights for future Sjögren's disease research.
The Health sector on Pluang saw 44 of 100 US stocks rise and 52 fall as of Oct 08, 2026 12:11 WIB, providing context for argenx's update on its Phase 3 UNITY study of efgartigimod SC in Sjögren's disease. Among notable movers, ABEO rose 3.39% to USD 5.18 with 100% buy orders and a typical hold time of 24 days, while TDOC fell 3.38% to USD 5.58 and ADPT declined 2.75% to USD 26.16, also with 100% buy orders and a 36-day hold time.
FLSmidth secured a DKK 360 million contract to supply advanced crushing and grinding equipment for a copper mine expansion in Northern Chile. The order includes the world's largest gyratory crusher, a large SAG mill, and three ball mills, with instal...
On October 8, 2026, Michelin repurchased 202,417 of its own ordinary shares at a weighted average price of €32.33 per share through over-the-counter transactions. The shares bought back are intended for cancellation, which can reduce the total number...
On October 8, 2026, Michelin executed a share buyback, purchasing 202,417 ordinary shares at a weighted average price of €32.33 per share. The shares were acquired through over-the-counter transactions involving several financial institutions and are...
FORVIA HELLA has secured two significant series orders for its EnergyCore solutions, including its first 3-in-1 high-voltage battery management system and a 48-volt PowerPack. These integrated systems reduce vehicle cost, complexity, weight, and spac...
Bavarian Nordic A/S has upgraded its financial outlook for 2026 due to stronger-than-expected sales in its Travel Health segment, particularly driven by increased demand for rabies vaccines in the U.S. amid rising rabies exposure. The company now exp...
